Ann: Investor Presentation, page-583

If only such endeavour, rigour and energy was put in with actual discussion of CYP....by CYP holders.

@gavint66 do be a good lad and stop "ranting on this forum about CYP and the dangers of iPSC therapy" and actually follow your own advice in it being "very easy to access research."

Perhaps sit down with your medically learned siblings and get them to help you understand how tumorigenecity risks are well known and understood by the rather bright researchers involved in IPSC production and trials:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347549/#:~:text=The%20ectopic%20transcription%20of%20Oct4,oncogenetics%20%5B22%2C%2024%5D.

Whilst you of course think IPSC's the "new kid on the block" the risks you insist on incorrectly warning us all about have been being looked at for decades, in fact one could summise, as others have, that "the interaction between pluripotent stem cells and cancer immunotherapy has been studied for over a century" - Schöne et al. uncovered the fact that immunization with embryonic tissue encouraged rejection of transplanted tumors in mice in 1906! (Qjao et al 2020)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967018/

You are so yesterday Gavin:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494249/

Lets skip to the conclusion:

"For more than a decade, studies about the applications of iPSCs have mainly focused on the regenerative field. In this context, carcinogenesis and immunogenicity are two major obstacles that scientists should overcome. Therefore, plenty of researchers are focusing on either developing new reprogramming methods, or creating mutation screening protocols to circumvent tumor formation and immune response after transplantation. Nevertheless, these obstacles may provide iPSC unique characteristics that allow it to become a promising strategy in cancer immunotherapy. Moreover, an iPSC-based vaccine can easily compensate for disadvantages generated by oncofetal antigen-based and ESC-based vaccines. First, as a whole-cell based cancer vaccine, iPSCs can provide multiple oncofetal antigens, which can cover a wide range of tumor types and compensate for the heterogenicity within tumors. Second, an autologously developed iPSC vaccine can resolve the problem of MHC incompatibility, and therefore reduce the possibility of an immune response to MHC-related proteins. An iPSC vaccine can focus on the oncofetal peptides shared by pluripotent cells and neoplastic cells. Since using iPSC alone cannot induce a powerful anti-tumor immune response, future studies should focus on investigating safe and potent immunostimulatory adjuvants to help iPSCs elicit anti-tumor immunity. The other possible direction may be evaluating the synergic effects of combining iPSCs with other cancer-specific cells in a vaccine."

Brighter minds than yours, and mine, have been all over your concerns for over a decade.